The purpose of this study is to develop a strategy for identifying molecular markers of response of advanced prostate cancer to specific therapies. To achieve this goal we will use clinically relevant prostate cancer patient derived xenografts PDXs that are responders and nonresponders primary and secondary resistance to therapies that had demonstrated clinical activity. We will identify genomic alterations via integrative genomic analysis of these PDXs. The MD Anderson and Michigan Center for Translational Pathology teams will interact closely to analyze integrative genomic analysis results to generate a responder ID profile hypothesis. The validity of the responder ID profiles will be assessed in clinical trials. We had already identified prostate cancer PDXs responders and non-responders to a therapy that targets fibroblast growth factor receptors pathway. We are now generating tissue samples to perform integrative genomic analysis.